Channels

Sat, Oct 19 1:20am

0 Drug Manufacturers Industry

Sun, Oct 6 - Sat, Oct 12

Study the past if you would define the future.
Confucius

52 Week Lows

Sun, Oct 20 - Sat, Oct 26

The best way to predict the future is to create it.
Abraham Lincoln

Earnings Annoucements
392

Drug Manufacturers Industry

NVS $86.88 0.35 (0.40%)
Novartis AG Novartis
NYSE: NVS $203 Billion Large-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 13%. 1 Year Return 14%. 2019 YTD Return 18%. 3.3% dividend yield. 28 total dividend payments. Paid Annually. Earnings in 3 days on Tue, Oct 22. (Use the Earnings tab below to add this date to your calendar.)

NVS Profile

Market Cap 203 Billion
NVS Description

Novartis AG develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total sales.


Visit Website

NVS Earnings

EPS 2.94 P/E Ratio 15.59
Previous Thu, Jul 18, 2019
Latest Tue, Oct 22, 2019 (In 3 days)

NVS Dividend

Yield 3.26% / $2.83
Ex-Date Mon, Mar 4, 2019 (229 days ago)
Pay Date Wed, Mar 13, 2019
History 28 Payments (Annually)

NVS Charts

All Time High $95.00 set on Thu, Jul 18, 2019.
$72.05
1 Year
$95.00
Dec 27, 2018
Jul 18, 2019



    TOP    
AZN $43.87 0.26 (0.59%)
Astrazeneca AstraZeneca
NYSE: AZN $113 Billion Large-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 29%. 1 Year Return 12%. 2019 YTD Return 16%. 2.0% dividend yield. 51 total dividend payments. Paid Biannually. Earnings in 5 days on Thu, Oct 24. (Use the Earnings tab below to add this date to your calendar.)

AZN Profile

Market Cap 113 Billion
AZN Description

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The company sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology, and neuroscience. The majority of sales come from international markets with the United States representing close to one third of its sales.


Visit Website

AZN Earnings

EPS 0.05 P/E Ratio 46.84
Previous Thu, Jul 25, 2019
Latest Thu, Oct 24, 2019 (In 5 days)

AZN Dividend

Yield 2.04% / $0.90
Ex-Date Thu, Aug 9, 2018 (436 days ago)
Pay Date Mon, Sep 10, 2018
History 51 Payments (Biannual)

AZN Charts

All Time High $46.22 set on Thu, Sep 26, 2019.
$35.30
1 Year
$46.22
Jan 28, 2019
Sep 26, 2019



    TOP    
GSK $42.53 0.06 (0.14%)
GlaxoSmithKline
NYSE: GSK $102 Billion Large-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 2%. 1 Year Return 4%. 2019 YTD Return 12%. 4.4% dividend yield. 110 total dividend payments. Earnings in 11 days on Wed, Oct 30. (Use the Earnings tab below to add this date to your calendar.)

GSK Profile

Market Cap 102 Billion
GSK Description

In the pharmaceutical industry, GlaxoSmithKline ranks as one of the largest companies by total sales. The company wields its might across several therapeutic classes, including respiratory and antiviral, as well as vaccines and consumer healthcare products. Glaxo uses joint ventures to gain additional scale in certain markets like HIV and consumer products.


Visit Website

GSK Earnings

EPS 0.39 P/E Ratio 40.40
Previous Wed, Jul 24, 2019
Latest Wed, Oct 30, 2019 (In 11 days)

GSK Dividend

Yield 4.38% / $1.86
Ex-Date Thu, Aug 8, 2019 (72 days ago)
Pay Date Thu, Oct 10, 2019
History 110 Payments (Quarterly)

GSK Charts

$36.41
1 Year
$43.22
Dec 6, 2018
Sep 30, 2019



    TOP    
ELAN $26.23 0.24 (0.91%)
Elanco Animal Health
NYSE: ELAN $11 Billion Large-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 27%. 1 Year Return 17%. 2019 YTD Return 18%. Negative 5 year, 1 year & YTD returns. You may want to avoid this one until things turn around. Check out some Uptrending symbols instead. Earnings in 17 days on Tue, Nov 5. (Use the Earnings tab below to add this date to your calendar.)

ELAN Profile

Market Cap 11 Billion
ELAN Description

Elanco Animal Health Inc is a animal health company which is engaged in innovating, developing, manufacturing, and marketing products for companion and food animals. Geographically, the company derives revenue from North America, Europe, the Middle East and Africa, Latin America, and Asia Pacific with highest revenue from North America segment.


Visit Website

ELAN Earnings

EPS 0.10 P/E Ratio 0.00
Previous Tue, Aug 13, 2019
Latest Tue, Nov 5, 2019 (In 17 days)

ELAN Dividend

Yield --
Ex-Date --
Pay Date --
History --

ELAN Charts

52 Week Low $25.51 set on Tue, Aug 27, 2019
$25.51
1 Year
$35.46
Aug 27, 2019
Jun 26, 2019



    TOP    
CGC $20.21 0.55 (2.65%)
Canopy Growth Corporation Common Stock
NYSE: CGC $10 Billion Mid-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 1,089%. 1 Year Return 57%. 2019 YTD Return 30%. Earnings in 25 days on Wed, Nov 13. (Use the Earnings tab below to add this date to your calendar.)

CGC Profile

Market Cap 10 Billion
CGC Description

Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.


Visit Website

CGC Earnings

EPS -3.70 P/E Ratio 0.00
Previous Wed, Aug 14, 2019
Latest Wed, Nov 13, 2019 (In 25 days)

CGC Dividend

Yield --
Ex-Date --
Pay Date --
History --

CGC Charts

52 Week Low $17.89 set on Mon, Oct 14, 2019
$17.89
1 Year
$52.74
Oct 14, 2019
Apr 30, 2019



    TOP    
BHC $22.54 0.26 (1.14%)
Bausch Health Companies Inc. Common Stock
NYSE: BHC $8 Billion Mid-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 82%. 1 Year Return 7%. 2019 YTD Return 11%. Earnings in 16 days on Mon, Nov 4. (Use the Earnings tab below to add this date to your calendar.)

BHC Profile

Market Cap 8 Billion
BHC Description

Bausch Health Companies Inc is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets.


Visit Website

BHC Earnings

EPS -0.49 P/E Ratio 0.00
Previous Tue, Aug 6, 2019
Latest Mon, Nov 4, 2019 (In 16 days)

BHC Dividend

Yield --
Ex-Date --
Pay Date --
History 22 Payments (Quarterly)

BHC Charts

$17.20
1 Year
$27.72
Dec 26, 2018
Nov 8, 2018



    TOP    
CTLT $48.63 1.10 (2.21%)
Catalent Inc
NYSE: CTLT $8 Billion Mid-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 103%. 1 Year Return 18%. 2019 YTD Return 57%. Earnings in 17 days on Tue, Nov 5. (Use the Earnings tab below to add this date to your calendar.)

CTLT Profile

Market Cap 8 Billion
CTLT Description

Catalent is a specialty and generic drug manufacturing company. The company focuses on advanced delivery technologies and development solutions for drugs, biologics, and consumer health products. The vast majority of Catalent's sales are generated in the United States, followed by Europe and the rest of the world. Most of the company's sales are derived from branded drug products. The company considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.


Visit Website

CTLT Earnings

EPS 0.45 P/E Ratio 43.53
Previous Tue, Aug 27, 2019
Latest Tue, Nov 5, 2019 (In 17 days)

CTLT Dividend

Yield --
Ex-Date --
Pay Date --
History --

CTLT Charts

$29.23
1 Year
$58.38
Dec 24, 2018
Jul 30, 2019



    TOP    
RDY $38.71 0.80 (2.11%)
Dr. Reddy's Laboratories Ltd Common Stock
NYSE: RDY $6 Billion Mid-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 21%. 1 Year Return 12%. 2019 YTD Return 3%. 0.8% dividend yield. 20 total dividend payments. Paid Annually.

RDY Profile

Market Cap 6 Billion
RDY Description

With headquarters in India, Dr. Reddy's Laboratories develops and manufactures generic pharmaceuticals. The firm operates in three divisions: global generics, pharmaceutical services and active ingredients, and proprietary products and other, which make up most of the company's revenue at about 80%, 15%, and 3%, respectively. Most of the company's sales are based in the United States.


Visit Website

RDY Earnings

EPS 39.98 P/E Ratio 26.17
Previous --
Latest --

RDY Dividend

Yield 0.77% / $0.29
Ex-Date Fri, Jul 13, 2018 (463 days ago)
Pay Date Thu, Aug 9, 2018
History 20 Payments (Annually)

RDY Charts

$31.69
1 Year
$42.82
Oct 30, 2018
May 7, 2019



    TOP    
ACB $3.68 0.21 (5.40%)
Aurora Cannabis Inc. Common Shares
NYSE: ACB $6 Billion Mid-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 1,372%. 1 Year Return 63%. 2019 YTD Return 30%. Earnings in 23 days on Mon, Nov 11. (Use the Earnings tab below to add this date to your calendar.)

ACB Profile

Market Cap 6 Billion
ACB Description

Aurora Cannabis Inc., headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that include Aurora, CanniMed, MedReleaf, and San Rafael '71. Although the company primarily operates in Canada, Aurora has expanded internationally through medical cannabis exporting agreements or cultivation facilities in more than 20 countries.


Visit Website

ACB Earnings

EPS 0.02 P/E Ratio 31.99
Previous Wed, Sep 11, 2019
Latest Mon, Nov 11, 2019 (In 23 days)

ACB Dividend

Yield --
Ex-Date --
Pay Date --
History --

ACB Charts

52 Week Low $3.40 set on Mon, Oct 14, 2019
$3.40
1 Year
$10.90
Oct 14, 2019
Oct 19, 2018



    TOP    
HZNP $27.40 1.08 (3.79%)
Horizon Pharma PLC
NASDAQ: HZNP $5 Billion Mid-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 130%. 1 Year Return 44%. 2019 YTD Return 37%. Earnings in 18 days on Wed, Nov 6. (Use the Earnings tab below to add this date to your calendar.)

HZNP Profile

Market Cap 5 Billion
HZNP Description

Horizon Therapeutics PLC is a specialty and generic drug manufacturing company. The company is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. The company has two reportable segments: orphan and rheumatology segment and the primary care segment. It markets medicines in the areas of orphan diseases, rheumatology and primary care. The majority of revenue is generated in the United States.


Visit Website

HZNP Earnings

EPS -0.03 P/E Ratio 0.00
Previous Wed, Aug 7, 2019
Latest Wed, Nov 6, 2019 (In 18 days)

HZNP Dividend

Yield --
Ex-Date --
Pay Date --
History --

HZNP Charts

$16.56
1 Year
$29.44
Oct 26, 2018
Feb 28, 2019



    TOP    
GWPH $118.11 1.01 (0.85%)
GW Pharmaceuticals Plc - American Depositary Shares
NASDAQ: GWPH $4 Billion Mid-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 74%. 1 Year Return 17%. 2019 YTD Return 17%. Earnings in 17 days on Tue, Nov 5. (Use the Earnings tab below to add this date to your calendar.)

GWPH Profile

Market Cap 4 Billion
GWPH Description

GW Pharmaceuticals PLC is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. Its business activities are functioned through three reportable segments which are Commercial, Sativex Research and Development and Pipeline Research and Development. The company's lead product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol used for the treatment of a number of rare childhood-onset epilepsy disorders. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. Geographically its presence can be seen across the region of UK, Europe, US, Canada, and others.


Visit Website

GWPH Earnings

EPS 2.52 P/E Ratio 0.00
Previous Tue, Aug 6, 2019
Latest Tue, Nov 5, 2019 (In 17 days)

GWPH Dividend

Yield --
Ex-Date --
Pay Date --
History --

GWPH Charts

$90.14
1 Year
$196.00
Dec 27, 2018
May 7, 2019



    TOP    
CRON $8.32 0.54 (6.09%)
Cronos Group Inc. - Common Share
NASDAQ: CRON $4 Billion Mid-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 9%. 1 Year Return 14%. 2019 YTD Return 26%. Earnings in 24 days on Tue, Nov 12. (Use the Earnings tab below to add this date to your calendar.)

CRON Profile

Market Cap 4 Billion
CRON Description

Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth and has announced the acquisition of Redwood Holdings to sell CBD in the U.S.


Visit Website

CRON Earnings

EPS 0.75 P/E Ratio 0.00
Previous Thu, Aug 8, 2019
Latest Tue, Nov 12, 2019 (In 24 days)

CRON Dividend

Yield --
Ex-Date --
Pay Date --
History --

CRON Charts

$6.50
1 Year
$25.10
Oct 30, 2018
Feb 4, 2019



    TOP    
MDCO $56.99 1.00 (1.79%)
The Medicines Co
NASDAQ: MDCO $4 Billion Mid-Cap. New ALL-TIME HIGH today. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 152%. 1 Year Return 112%. 2019 YTD Return 207%. Earnings in 26 days on Thu, Nov 14. (Use the Earnings tab below to add this date to your calendar.)

MDCO Profile

Market Cap 4 Billion
MDCO Description

The Medicines Company is a pharmaceutical firm that provides products to the U.S. hospital market. The company's primary commercial product, Angiomax, is an anticoagulant drug used in conjunction with aspirin for patients undergoing angioplasty. Medicines recently commercialized a new drug, Cleviprex, which is designed to control blood pressure in intensive-care settings.


Visit Website

MDCO Earnings

EPS -0.80 P/E Ratio 0.00
Previous Wed, Jul 24, 2019
Latest Thu, Nov 14, 2019 (In 26 days)

MDCO Dividend

Yield --
Ex-Date --
Pay Date --
History --

MDCO Charts

All Time High $57.43 set on Fri, Oct 18, 2019.
$16.69
1 Year
$57.43
Dec 21, 2018
Today



    TOP    
TARO $75.71 0.32 (0.42%)
Taro Pharmaceutical Industries Ltd
NYSE: TARO $3 Billion Mid-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 46%. 1 Year Return 20%. 2019 YTD Return 12%. Negative 5 year, 1 year & YTD returns. You may want to avoid this one until things turn around. Check out some Uptrending symbols instead. 0.2% dividend yield. 9 total dividend payments. Earnings in 16 days on Mon, Nov 4. (Use the Earnings tab below to add this date to your calendar.)

TARO Profile

Market Cap 3 Billion
TARO Description

Taro Pharmaceutical Industries Ltd produces, researches, develops and markets pharmaceutical products. Its primary focus includes semi-solids formulations, such as creams and ointments and other dosage forms such as liquids, capsules, and tablets. The company is engaged in the dermatological and topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories. Geographically, it derives a majority of revenue from the United States and also has a presence in Canada, Israel, and Other Countries.


Visit Website

TARO Earnings

EPS 1.72 P/E Ratio 13.19
Previous Thu, Aug 8, 2019
Latest Mon, Nov 4, 2019 (In 16 days)

TARO Dividend

Yield 0.18% / $0.14
Ex-Date Tue, Mar 19, 2019 (214 days ago)
Pay Date Tue, Mar 26, 2019
History 9 Payments (Quarterly)

TARO Charts

52 Week Low $72.97 set on Wed, Oct 2, 2019
$72.97
1 Year
$109.42
Oct 2, 2019
Apr 29, 2019



    TOP    
TLRY $21.37 1.12 (4.98%)
Tilray Inc
NASDAQ: TLRY $3 Billion Mid-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 5%. 1 Year Return 85%. 2019 YTD Return 70%. Negative 5 year, 1 year & YTD returns. You may want to avoid this one until things turn around. Check out some Uptrending symbols instead. Earnings in 24 days on Tue, Nov 12. (Use the Earnings tab below to add this date to your calendar.)

TLRY Profile

Market Cap 3 Billion
TLRY Description

Tilray, headquartered in Nanaimo, Canada cultivates and sells medical and recreational cannabis through a portfolio of brands that include Canaca, Dubon, and Manitoba Harvest. The bulk of Tilray's sales are in Canada, but the company also sells CBD Products in the U.S. through a partnership with Authentic Brands Group and exports medical cannabis globally from its production facilities in Canada and Portugal. Tilray also has a partnership with AB InBev to develop cannabis-infused drinks.


Visit Website

TLRY Earnings

EPS -0.36 P/E Ratio 0.00
Previous Tue, Aug 13, 2019
Latest Tue, Nov 12, 2019 (In 24 days)

TLRY Dividend

Yield --
Ex-Date --
Pay Date --
History --

TLRY Charts

52 Week Low $20.20 set on Mon, Oct 14, 2019
$20.20
1 Year
$159.28
Oct 14, 2019
Oct 19, 2018



    TOP    
HCM $19.12 0.63 (3.19%)
Hutchison China MediTech Limited - American Depositary Shares
NASDAQ: HCM $3 Billion Mid-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 43%. 1 Year Return 37%. 2019 YTD Return 16%.

HCM Profile

Market Cap 3 Billion
HCM Description

Hutchison China Meditech Ltd is a major drug manufacturing company. The company operates two platforms- an innovation platform and a commercial platform. Hutchison's innovation platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases. The company's commercial platform includes the manufacturing, marketing, and distribution of prescription and over-the-counter pharmaceuticals in China as well as certain consumer products in Hong Kong. The vast majority of the company's revenue is generated through its commercial platform.


Visit Website

HCM Earnings

EPS -0.20 P/E Ratio 0.00
Previous --
Latest --

HCM Dividend

Yield --
Ex-Date --
Pay Date --
History --

HCM Charts

52 Week Low $16.47 set on Mon, Sep 30, 2019
$16.47
1 Year
$39.68
Sep 30, 2019
Nov 14, 2018



    TOP    
ZGNX $42.59 2.02 (4.53%)
Zogenix Inc
NASDAQ: ZGNX $2 Million Small-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 286%. 1 Year Return 3%. 2019 YTD Return 12%. Earnings in 26 days on Thu, Nov 14. (Use the Earnings tab below to add this date to your calendar.)

ZGNX Profile

Market Cap 2 Billion
ZGNX Description

Zogenix Inc is engaged in developing and commercializing therapeutic solutions for people living with serious and life-threatening rare CNS disorders and medical conditions. Its product candidate includes ZX008, low-dose fenfluramine for the treatment of Dravet syndrome, LGS, and potentially other rare and catastrophic epilepsy disorders.


Visit Website

ZGNX Earnings

EPS -0.89 P/E Ratio 0.00
Previous Tue, Aug 6, 2019
Latest Thu, Nov 14, 2019 (In 26 days)

ZGNX Dividend

Yield --
Ex-Date --
Pay Date --
History --

ZGNX Charts

$33.43
1 Year
$56.50
Dec 24, 2018
Mar 29, 2019



    TOP    
APHA $4.75 0.18 (3.65%)
Aphria Inc. Common Shares
NYSE: APHA $2 Million Small-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 560%. 1 Year Return 66%. 2019 YTD Return 21%. Since Earnings 9%.

APHA Profile

Market Cap 2 Billion
APHA Description

Aphria Inc and its subsidiaries produce and sell medical marijuana. Its products include Capsules, Oral solutions, and Vaporizers. The company's operations are based in Leamington, Ontario. It is focused on producing and selling medical marijuana and its derivatives through retail sales and wholesale channels. It operates through following segments: Cannabis operations which encompasses the production, distribution and sale of both medical and adult-use cannabis, Distribution operations and Businesses under development segment.


Visit Website

APHA Earnings

EPS 0.06 P/E Ratio 32.76
Previous Thu, Aug 1, 2019
Latest Tue, Oct 15, 2019 (4 days ago) Price +8.94%

APHA Dividend

Yield --
Ex-Date --
Pay Date --
History --

APHA Charts

$3.75
1 Year
$15.41
Dec 6, 2018
Oct 19, 2018



    TOP    
TCDA $35.40 0.47 (1.35%)
Tricida Inc
NASDAQ: TCDA $2 Million Small-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 36%. 1 Year Return 18%. 2019 YTD Return 53%. Earnings in 26 days on Thu, Nov 14. (Use the Earnings tab below to add this date to your calendar.)

TCDA Profile

Market Cap 2 Billion
TCDA Description

Tricida Inc is a late-stage pharmaceutical company. It is engaged in the development of novel therapeutics to address renal, metabolic and cardiovascular disease. The primary area of focus is to slow the progression of chronic kidney disease through the treatment of metabolic acidosis.


Visit Website

TCDA Earnings

EPS -0.75 P/E Ratio 0.00
Previous Thu, Aug 8, 2019
Latest Thu, Nov 14, 2019 (In 26 days)

TCDA Dividend

Yield --
Ex-Date --
Pay Date --
History --

TCDA Charts

$19.43
1 Year
$42.80
Jan 30, 2019
Jul 1, 2019



    TOP    
HRTX $18.45 0.15 (0.81%)
Heron Therapeutics Inc
NASDAQ: HRTX $2 Million Small-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 151%. 1 Year Return 37%. 2019 YTD Return 29%. Earnings in 18 days on Wed, Nov 6. (Use the Earnings tab below to add this date to your calendar.)

HRTX Profile

Market Cap 2 Billion
HRTX Description

Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of SUSTOL and CINVANTI. Its pipeline product is HTX-011.


Visit Website

HRTX Earnings

EPS -0.63 P/E Ratio 0.00
Previous Mon, Aug 5, 2019
Latest Wed, Nov 6, 2019 (In 18 days)

HRTX Dividend

Yield --
Ex-Date --
Pay Date --
History --

HRTX Charts

$15.68
1 Year
$31.81
Aug 7, 2019
Nov 2, 2018



    TOP    
PCRX $38.85 0.07 (0.18%)
Pacira Pharmaceuticals Inc
NASDAQ: PCRX $2 Million Small-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 61%. 1 Year Return 17%. 2019 YTD Return 7%. Negative 5 year, 1 year & YTD returns. You may want to avoid this one until things turn around. Check out some Uptrending symbols instead. Earnings in 19 days on Thu, Nov 7. (Use the Earnings tab below to add this date to your calendar.)

PCRX Profile

Market Cap 2 Billion
PCRX Description

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for health care practitioners and their patients. The company have launched EXPAREL which utilizes DepoFoam, a product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time.


Visit Website

PCRX Earnings

EPS 0.07 P/E Ratio 0.00
Previous Thu, May 2, 2019
Latest Thu, Aug 8, 2019 (72 days ago) Price +0.00%

PCRX Dividend

Yield --
Ex-Date --
Pay Date --
History --

PCRX Charts

$34.64
1 Year
$55.00
Sep 9, 2019
Nov 2, 2018



    TOP    
IRWD $8.74 0.32 (3.53%)
Ironwood Pharmaceuticals Inc
NASDAQ: IRWD $2 Million Small-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 20%. 1 Year Return 38%. 2019 YTD Return 1%. Earnings in 17 days on Tue, Nov 5. (Use the Earnings tab below to add this date to your calendar.)

IRWD Profile

Market Cap 2 Billion
IRWD Description

Ironwood Pharmaceuticals is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing innovative product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.


Visit Website

IRWD Earnings

EPS 0.08 P/E Ratio 0.00
Previous Tue, Jul 30, 2019
Latest Tue, Nov 5, 2019 (In 17 days)

IRWD Dividend

Yield --
Ex-Date --
Pay Date --
History --

IRWD Charts

$7.59
1 Year
$14.66
Dec 24, 2018
Oct 19, 2018



    TOP    
SUPN $25.67 0.92 (3.46%)
Supernus Pharmaceuticals Inc
NASDAQ: SUPN $1 Million Small-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 230%. 1 Year Return 47%. 2019 YTD Return 22%. Earnings in 17 days on Tue, Nov 5. (Use the Earnings tab below to add this date to your calendar.)

SUPN Profile

Market Cap 1 Billion
SUPN Description

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders.


Visit Website

SUPN Earnings

EPS 0.62 P/E Ratio 18.03
Previous Tue, May 7, 2019
Latest Tue, Aug 6, 2019 (74 days ago) Price +0.00%

SUPN Dividend

Yield --
Ex-Date --
Pay Date --
History --

SUPN Charts

52 Week Low $24.77 set on Tue, Oct 15, 2019
$24.77
1 Year
$49.25
Oct 15, 2019
Dec 3, 2018



    TOP    
MNTA $14.40 0.25 (1.77%)
Momenta Pharmaceuticals Inc
NASDAQ: MNTA $1 Million Small-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 28%. 1 Year Return 5%. 2019 YTD Return 27%. Earnings in 18 days on Wed, Nov 6. (Use the Earnings tab below to add this date to your calendar.) "Possible" Golden Cross chart pattern.

MNTA Profile

Market Cap 1 Billion
MNTA Description

Momenta is a biotechnology company focused on the characterization and development of innovative drugs in autoimmune diseases. Its legacy business includes complex generic versions of MS drug Copaxone and anticoagulant Lovenox, and it receives royalties for these products through a partnership with Novartis. While biosimilar versions of Humira and Eylea are in the pipeline, Momenta terminated future development in generics/biosimilars in 2018. Several innovative drugs, including M281, M254, and M230, are in development to treat rare autoimmune diseases.


Visit Website

MNTA Earnings

EPS -1.16 P/E Ratio 0.00
Previous Fri, Aug 2, 2019
Latest Wed, Nov 6, 2019 (In 18 days)

MNTA Dividend

Yield --
Ex-Date --
Pay Date --
History --

MNTA Charts

$9.51
1 Year
$16.11
Jul 22, 2019
Feb 22, 2019



    TOP    
OPK $2.10 0.07 (3.23%)
OPKO Health Inc
NASDAQ: OPK $1 Million Small-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 75%. 1 Year Return 42%. 2019 YTD Return 36%. Negative 5 year, 1 year & YTD returns. You may want to avoid this one until things turn around. Check out some Uptrending symbols instead. Earnings in 20 days on Fri, Nov 8. (Use the Earnings tab below to add this date to your calendar.)

OPK Profile

Market Cap 1 Billion
OPK Description

Opko Health is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a global supply-chain operation and holding company in Ireland. Opko also owns a specialty active pharmaceutical ingredients manufacturer in Israel. The company's bio-reference testing business consists of routine testing and esoteric testing. Routine tests measure various health parameters, such as the functions of the heart, kidney, liver, thyroid, and other organs.


Visit Website

OPK Earnings

EPS -0.10 P/E Ratio 0.00
Previous Wed, Aug 7, 2019
Latest Fri, Nov 8, 2019 (In 20 days)

OPK Dividend

Yield --
Ex-Date --
Pay Date --
History --

OPK Charts

$1.73
1 Year
$3.94
May 31, 2019
Jan 11, 2019



    TOP    
RDUS $27.31 0.30 (1.09%)
Radius Health Inc
NASDAQ: RDUS $1 Million Small-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 46%. 1 Year Return 44%. 2019 YTD Return 62%. Earnings in 19 days on Thu, Nov 7. (Use the Earnings tab below to add this date to your calendar.)

RDUS Profile

Market Cap 1 Billion
RDUS Description

Radius Health Inc is an integrated biopharmaceutical company. It develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company's product, TYMLOS, is for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. The product pipeline of the company includes Abaloparatide-patch for the treatment of postmenopausal women with osteoporosis, Elacestrant, and RAD140. It primarily operates the business in the United States of America and generates key revenue from the sales of TYMLOS.


Visit Website

RDUS Earnings

EPS -0.77 P/E Ratio 0.00
Previous Wed, Aug 7, 2019
Latest Thu, Nov 7, 2019 (In 19 days)

RDUS Dividend

Yield --
Ex-Date --
Pay Date --
History --

RDUS Charts

$12.81
1 Year
$29.97
Dec 24, 2018
Sep 17, 2019



    TOP    
AMRX $2.99 0.02 (0.66%)
Amneal Pharmaceuticals Inc
NYSE: AMRX $1 Million Small-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 80%. 1 Year Return 84%. 2019 YTD Return 79%. Negative 5 year, 1 year & YTD returns. You may want to avoid this one until things turn around. Check out some Uptrending symbols instead. Earnings in 18 days on Wed, Nov 6. (Use the Earnings tab below to add this date to your calendar.)

AMRX Profile

Market Cap 1 Billion
AMRX Description

Amneal Pharmaceuticals Inc is a generic pharmaceutical manufacturer. The company's reportable segments are Generic Products and Specialty products. Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals, and Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products. It generates a majority of its revenue from the Generic business segment.


Visit Website

AMRX Earnings

EPS -0.13 P/E Ratio 0.00
Previous Mon, Aug 5, 2019
Latest Wed, Nov 6, 2019 (In 18 days)

AMRX Dividend

Yield --
Ex-Date --
Pay Date --
History --

AMRX Charts

$2.27
1 Year
$21.22
Aug 27, 2019
Nov 7, 2018



    TOP    
AERI $20.51 0.74 (3.48%)
Aerie Pharmaceuticals Inc
NASDAQ: AERI $1 Million Small-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 6%. 1 Year Return 65%. 2019 YTD Return 44%. Negative 5 year, 1 year & YTD returns. You may want to avoid this one until things turn around. Check out some Uptrending symbols instead. Earnings in 17 days on Tue, Nov 5. (Use the Earnings tab below to add this date to your calendar.)

AERI Profile

Market Cap 1 Billion
AERI Description

Aerie Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on discovery, development, and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. Its main products are Rhopressa and Roclatan. The company mainly operates in North America.


Visit Website

AERI Earnings

EPS -1.04 P/E Ratio 0.00
Previous Wed, Aug 7, 2019
Latest Tue, Nov 5, 2019 (In 17 days)

AERI Dividend

Yield --
Ex-Date --
Pay Date --
History --

AERI Charts

52 Week Low $17.51 set on Thu, Oct 10, 2019
$17.51
1 Year
$60.05
Oct 10, 2019
Oct 23, 2018



    TOP    
AMPH $19.93 0.59 (2.88%)
Amphastar Pharmaceuticals Inc
NASDAQ: AMPH $1 Million Small-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 93%. 1 Year Return 8%. 2019 YTD Return 1%. Earnings in 26 days on Thu, Nov 14. (Use the Earnings tab below to add this date to your calendar.)

AMPH Profile

Market Cap 1 Billion
AMPH Description

Amphastar Pharmaceuticals Inc is a specialty pharmaceutical company engaged in developing, manufacturing, marketing and selling generic and proprietary injectable and inhalation products. The business activities are operated through two reportable segments namely finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, naloxone, lidocaine, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API. Its products are used in hospitals or urgent care clinical settings. Geographically the business presence of the firm is seen in the United States and France of which the US accounts for the majority of revenue.


Visit Website

AMPH Earnings

EPS 1.01 P/E Ratio 0.00
Previous Wed, Aug 7, 2019
Latest Thu, Nov 14, 2019 (In 26 days)

AMPH Dividend

Yield --
Ex-Date --
Pay Date --
History --

AMPH Charts

$17.71
1 Year
$25.43
Oct 24, 2018
Mar 4, 2019



    TOP    
PAHC $21.09 0.35 (1.63%)
Phibro Animal Health Corp
NASDAQ: PAHC $880 Million Small-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 13%. 1 Year Return 52%. 2019 YTD Return 34%. Negative 5 year, 1 year & YTD returns. You may want to avoid this one until things turn around. Check out some Uptrending symbols instead. 2.3% dividend yield. 21 total dividend payments. Earnings in 17 days on Tue, Nov 5. (Use the Earnings tab below to add this date to your calendar.)

PAHC Profile

Market Cap 880 Million
PAHC Description

Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the US and other international countries.


Visit Website

PAHC Earnings

EPS 0.22 P/E Ratio 20.83
Previous Tue, Aug 27, 2019
Latest Tue, Nov 5, 2019 (In 17 days)

PAHC Dividend

Yield 2.28% / $0.48
Ex-Date Tue, Sep 3, 2019 (46 days ago)
Pay Date Wed, Sep 25, 2019
History 21 Payments (Quarterly)

PAHC Charts

52 Week Low $20.00 set on Tue, Sep 3, 2019
$20.00
1 Year
$44.99
Sep 3, 2019
Oct 23, 2018



    TOP    
TXMD $3.67 0.07 (1.87%)
TherapeuticsMD Inc
NASDAQ: TXMD $800 Million Small-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 9%. 1 Year Return 33%. 2019 YTD Return 5%. Negative 5 year, 1 year & YTD returns. You may want to avoid this one until things turn around. Check out some Uptrending symbols instead. Earnings in 18 days on Wed, Nov 6. (Use the Earnings tab below to add this date to your calendar.)

TXMD Profile

Market Cap 800 Million
TXMD Description

TherapeuticsMD Inc is a major drug manufacturing with a focus on creating and commercializing products targeted exclusively for women. The company intends to commercialize advanced hormone therapy pharmaceutical products. TherapeuticsMD's drug candidates that have completed clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and discomfort. The company relies on third parties for the production of clinical and commercial quantities of its drug candidates.


Visit Website

TXMD Earnings

EPS -0.23 P/E Ratio 0.00
Previous Tue, Aug 6, 2019
Latest Wed, Nov 6, 2019 (In 18 days)

TXMD Dividend

Yield --
Ex-Date --
Pay Date --
History --

TXMD Charts

$1.82
1 Year
$6.09
Aug 6, 2019
Mar 4, 2019



    TOP    
EGRX $61.71 0.80 (1.28%)
Eagle Pharmaceuticals Inc
NASDAQ: EGRX $790 Million Small-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 407%. 1 Year Return 6%. 2019 YTD Return 52%. Earnings in 19 days on Thu, Nov 7. (Use the Earnings tab below to add this date to your calendar.)

EGRX Profile

Market Cap 790 Million
EGRX Description

Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, docetaxel injection, non-alcohol formulation and Bendeka. The company currently have multiple product candidates in advanced stages of development, and under review for approval by the Food and Drug Administration.


Visit Website

EGRX Earnings

EPS 0.49 P/E Ratio 26.46
Previous Thu, Aug 8, 2019
Latest Thu, Nov 7, 2019 (In 19 days)

EGRX Dividend

Yield --
Ex-Date --
Pay Date --
History --

EGRX Charts

$36.03
1 Year
$62.98
Dec 24, 2018
Oct 15, 2019



    TOP    
PETQ $23.97 1.73 (6.73%)
PetIQ Inc
NASDAQ: PETQ $750 Million Small-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 3%. 1 Year Return 29%. 2019 YTD Return 1%. Earnings in 24 days on Tue, Nov 12. (Use the Earnings tab below to add this date to your calendar.)

PETQ Profile

Market Cap 750 Million
PETQ Description

PetIQ Inc is a manufacturer and distributor of health and wellness products for dogs and cats. The company offers veterinarian-grade pet Rx medications, OTC flea and tick preventatives, vitamins treats, nutritional supplements, and hygiene products. The group operates in two segments namely the Product and Service segments. It also provides third-party products to retailers which for a long time were primarily available from veterinary clinics only. Its proprietary brands include Advecta, Betsy Farms, Mimi's Market, PetAction and TruProfen. It operates mainly in the United States, Canada, and Europe.


Visit Website

PETQ Earnings

EPS 0.17 P/E Ratio 0.00
Previous Wed, Aug 7, 2019
Latest Tue, Nov 12, 2019 (In 24 days)

PETQ Dividend

Yield --
Ex-Date --
Pay Date --
History --

PETQ Charts

$21.29
1 Year
$36.33
Dec 24, 2018
Jul 23, 2019



    TOP    
KPTI $10.70 0.16 (1.47%)
Karyopharm Therapeutics Inc
NASDAQ: KPTI $680 Million Small-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 69%. 1 Year Return 13%. 2019 YTD Return 12%. Earnings in 26 days on Thu, Nov 14. (Use the Earnings tab below to add this date to your calendar.)

KPTI Profile

Market Cap 680 Million
KPTI Description

Karyopharm Therapeutics Inc is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. The pipeline products of the company include Oral Selinexor, Oral Eltanexor, Oral Dual Inhibitor of PAK4 and NAMPT and Oral Verdinexor.


Visit Website

KPTI Earnings

EPS -0.71 P/E Ratio 0.00
Previous Tue, Aug 6, 2019
Latest Thu, Nov 14, 2019 (In 26 days)

KPTI Dividend

Yield --
Ex-Date --
Pay Date --
History --

KPTI Charts

$3.92
1 Year
$12.84
Mar 1, 2019
Oct 19, 2018



    TOP    
CPRX $5.25 0.05 (0.94%)
Catalyst Pharmaceuticals Inc
NASDAQ: CPRX $640 Million Small-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 114%. 1 Year Return 59%. 2019 YTD Return 149%. Earnings in 18 days on Wed, Nov 6. (Use the Earnings tab below to add this date to your calendar.)

CPRX Profile

Market Cap 640 Million
CPRX Description

Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome.


Visit Website

CPRX Earnings

EPS 0.11 P/E Ratio 0.00
Previous Wed, Aug 7, 2019
Latest Wed, Nov 6, 2019 (In 18 days)

CPRX Dividend

Yield --
Ex-Date --
Pay Date --
History --

CPRX Charts

$1.85
1 Year
$7.67
Dec 21, 2018
Sep 11, 2019



    TOP    
FLXN $14.24 0.18 (1.25%)
Flexion Therapeutics Inc
NASDAQ: FLXN $530 Million Small-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 14%. 1 Year Return 25%. 2019 YTD Return 14%. Earnings in 18 days on Wed, Nov 6. (Use the Earnings tab below to add this date to your calendar.)

FLXN Profile

Market Cap 530 Million
FLXN Description

Flexion Therapeutics Inc is a United States-based specialty pharmaceutical company. The company focuses on the development and commercialization of novel, local therapies. The company specializes in the treatment of patients with musculoskeletal conditions beginning with osteoarthritis. The products offered by company are zilretta which is used for enhancing clinical effect of intra articular corticosteroid treatment.


Visit Website

FLXN Earnings

EPS -0.96 P/E Ratio 0.00
Previous Tue, Aug 6, 2019
Latest Wed, Nov 6, 2019 (In 18 days)

FLXN Dividend

Yield --
Ex-Date --
Pay Date --
History --

FLXN Charts

$8.76
1 Year
$19.36
Aug 5, 2019
Oct 19, 2018



    TOP    
RTRX $11.24 0.18 (1.58%)
Retrophin Inc
NASDAQ: RTRX $520 Million Small-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 17%. 1 Year Return 56%. 2019 YTD Return 50%. Earnings in 19 days on Thu, Nov 7. (Use the Earnings tab below to add this date to your calendar.)

RTRX Profile

Market Cap 520 Million
RTRX Description

Retrophin Inc serves in the healthcare sector based in the United States. As a pharmaceutical products manufacturer, it develops drugs to treat serious and rare diseases. Its suite of drug candidates includes Chenodal, to combat gallstones; Cholbam, which is approved for the treatment of bile acid synthesis disorders and Thiola, which addresses kidney stone formation.


Visit Website

RTRX Earnings

EPS -0.92 P/E Ratio 0.00
Previous Tue, Aug 6, 2019
Latest Thu, Nov 7, 2019 (In 19 days)

RTRX Dividend

Yield --
Ex-Date --
Pay Date --
History --

RTRX Charts

52 Week Low $10.87 set on Thu, Oct 10, 2019
$10.87
1 Year
$27.81
Oct 10, 2019
Nov 1, 2018



    TOP    
LCI $11.73 0.22 (1.84%)
Lannett Co Inc
NYSE: LCI $500 Million Small-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 73%. 1 Year Return 203%. 2019 YTD Return 119%. Earnings in 18 days on Wed, Nov 6. (Use the Earnings tab below to add this date to your calendar.)

LCI Profile

Market Cap 500 Million
LCI Description

Lannett Co Inc develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products. It offers solid oral, extended-release, topical, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, soft gel, and injectable dosages. In addition, the company also provides its products for various medical indications comprising glaucoma, gastrointestinal, migraine, obesity, respiratory and others. It operates in the segment of generic pharmaceuticals. Its customers include generic pharmaceutical distributors, drug wholesalers, chain drug stores, private label distributors, mail-order pharmacies, and others.


Visit Website

LCI Earnings

EPS -0.20 P/E Ratio 0.00
Previous Tue, Aug 27, 2019
Latest Wed, Nov 6, 2019 (In 18 days)

LCI Dividend

Yield --
Ex-Date --
Pay Date --
History --

LCI Charts

$3.33
1 Year
$15.52
Oct 26, 2018
Sep 13, 2019



    TOP    
DPLO $5.16 0.01 (0.19%)
Diplomat Pharmacy Inc
NYSE: DPLO $500 Million Small-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 73%. 1 Year Return 75%. 2019 YTD Return 63%. Negative 5 year, 1 year & YTD returns. You may want to avoid this one until things turn around. Check out some Uptrending symbols instead. This is clearly Downtrending. Avoid for now. Earnings in 17 days on Tue, Nov 5. (Use the Earnings tab below to add this date to your calendar.)

DPLO Profile

Market Cap 500 Million
DPLO Description

Diplomat Pharmacy Inc. is active in the U.S. healthcare sector. It provides specialty pharmacy and infusion services, including pharmacy solutions for chronic diseases. The company has two main segments: specialty pharmacy and pharmacy benefit management. Its specialty pharmacy segment offers solutions to dispense, deliver, and dose prescription drugs. The pharmacy benefit management segment offers services to help control pharmacy benefit dollars and maximize quality of care. It derives most of its revenue through prescription drug sales in the United States.


Visit Website

DPLO Earnings

EPS -2.13 P/E Ratio 374.25
Previous Fri, Aug 9, 2019
Latest Tue, Nov 5, 2019 (In 17 days)

DPLO Dividend

Yield --
Ex-Date --
Pay Date --
History --

DPLO Charts

$4.17
1 Year
$21.48
Jun 14, 2019
Nov 2, 2018



    TOP    
SLDB $11.80 0.48 (3.91%)
Solid Biosciences Inc
NASDAQ: SLDB $470 Million Small-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 48%. 1 Year Return 66%. 2019 YTD Return 59%. Negative 5 year, 1 year & YTD returns. You may want to avoid this one until things turn around. Check out some Uptrending symbols instead. Earnings in 24 days on Tue, Nov 12. (Use the Earnings tab below to add this date to your calendar.)

SLDB Profile

Market Cap 470 Million
SLDB Description

Solid Biosciences Inc is a life science company. It is engaged in manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. Its lead product candidate, the SGT-001, is a gene transfer under development to restore functional dystrophin protein expression in patients' muscles. The company's pipeline products are the SB-001 and solid suit. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices. In the assistive device program, the company focuses on producing a wearable assistive device for patients with DMD.


Visit Website

SLDB Earnings

EPS -0.76 P/E Ratio 0.00
Previous Wed, Aug 14, 2019
Latest Tue, Nov 12, 2019 (In 24 days)

SLDB Dividend

Yield --
Ex-Date --
Pay Date --
History --

SLDB Charts

$4.32
1 Year
$37.50
Jul 25, 2019
Nov 13, 2018



    TOP    
EOLS $15.20 0.20 (1.33%)
Evolus Inc
NASDAQ: EOLS $470 Million Small-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 32%. 1 Year Return 15%. 2019 YTD Return 22%. Earnings in 16 days on Mon, Nov 4. (Use the Earnings tab below to add this date to your calendar.)

EOLS Profile

Market Cap 470 Million
EOLS Description

Evolus Inc is engaged in providing physicians and their patients with expanded choices in medical aesthetic treatments and procedures. Its product candidate is an injectable formulation of a 900 kDa Botulinum toxin Type A complex. It has also completed the development program for DWP-450 for the treatment of moderate to severe glabellar lines.


Visit Website

EOLS Earnings

EPS -1.37 P/E Ratio 0.00
Previous Mon, Aug 12, 2019
Latest Mon, Nov 4, 2019 (In 16 days)

EOLS Dividend

Yield --
Ex-Date --
Pay Date --
History --

EOLS Charts

$10.22
1 Year
$30.25
Dec 24, 2018
Feb 11, 2019



    TOP    
AKRX $4.61 0.09 (1.91%)
Akorn Inc
NASDAQ: AKRX $420 Million Small-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 88%. 1 Year Return 34%. 2019 YTD Return 32%. Since Earnings 24%.

AKRX Profile

Market Cap 420 Million
AKRX Description

Akorn manufactures ophthalmology and dermatology products as well as injectables. In ophthalmology, the firm primarily sells generic and over-the-counter products but has a small branded portfolio that was purchased from Merck. The firm is primarily focused on the United States.


Visit Website

AKRX Earnings

EPS -0.89 P/E Ratio 0.00
Previous Tue, May 7, 2019
Latest Thu, Aug 1, 2019 (79 days ago) Price +23.92%

AKRX Dividend

Yield --
Ex-Date --
Pay Date --
History 0 Payments (Quarterly)

AKRX Charts

$2.34
1 Year
$7.52
Aug 15, 2019
Nov 5, 2018



    TOP    
COLL $11.56 0.52 (4.30%)
Collegium Pharmaceutical Inc
NASDAQ: COLL $400 Million Small-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 6%. 1 Year Return 30%. 2019 YTD Return 35%. Negative 5 year, 1 year & YTD returns. You may want to avoid this one until things turn around. Check out some Uptrending symbols instead. Earnings in 26 days on Thu, Nov 14. (Use the Earnings tab below to add this date to your calendar.)

COLL Profile

Market Cap 400 Million
COLL Description

Collegium Pharmaceutical Inc is a US-based specialty pharmaceutical company. It is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing and dissolving. The company's product Xtampza ER, is an abuse-deterrent, extended-release, oral formulation of oxycodone.


Visit Website

COLL Earnings

EPS -0.14 P/E Ratio 0.00
Previous Wed, Aug 7, 2019
Latest Thu, Nov 14, 2019 (In 26 days)

COLL Dividend

Yield --
Ex-Date --
Pay Date --
History --

COLL Charts

$10.01
1 Year
$19.83
Aug 2, 2019
Dec 6, 2018



    TOP    
DRRX $1.99 0.03 (1.53%)
Durect Corp
NASDAQ: DRRX $340 Million Small-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 51%. 1 Year Return 91%. 2019 YTD Return 269%. Earnings in 18 days on Wed, Nov 6. (Use the Earnings tab below to add this date to your calendar.)

DRRX Profile

Market Cap 340 Million
DRRX Description

Durect Corp is a biopharmaceutical company. It is engaged in the research, development and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and drug delivery programs. The company's pipeline products consist of DUR-928, RBP-7000, Remoxy, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan and other countries, of which key revenue is derived from Europe and the US.


Visit Website

DRRX Earnings

EPS -0.04 P/E Ratio 0.00
Previous Thu, Aug 1, 2019
Latest Wed, Nov 6, 2019 (In 18 days)

DRRX Dividend

Yield --
Ex-Date --
Pay Date --
History --

DRRX Charts

$0.46
1 Year
$2.46
Dec 28, 2018
Sep 23, 2019



    TOP    
OPTN $7.46 0.17 (2.33%)
OptiNose Inc
NASDAQ: OPTN $300 Million Small-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 61%. 1 Year Return 35%. 2019 YTD Return 9%. Earnings in 24 days on Tue, Nov 12. (Use the Earnings tab below to add this date to your calendar.)

OPTN Profile

Market Cap 300 Million
OPTN Description

OptiNose Inc is a US-based specialty pharmaceutical company which focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. The lead product of the company, XHANCE nasal spray, which utilizes proprietary breath powered exhalation delivery system, to deliver a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The XHANCE is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by intranasal steroids. The pipeline products of the company include XHANCE, OPN-300, OPN-021, and AVP-825.


Visit Website

OPTN Earnings

EPS -0.66 P/E Ratio 0.00
Previous Mon, Aug 12, 2019
Latest Tue, Nov 12, 2019 (In 24 days)

OPTN Dividend

Yield --
Ex-Date --
Pay Date --
History --

OPTN Charts

$4.44
1 Year
$12.05
Aug 7, 2019
Nov 7, 2018



    TOP    
RMTI $2.48 0.09 (3.77%)
Rockwell Medical Inc
NASDAQ: RMTI $200 Million Small-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 76%. 1 Year Return 42%. 2019 YTD Return 11%. Negative 5 year, 1 year & YTD returns. You may want to avoid this one until things turn around. Check out some Uptrending symbols instead. Earnings in 20 days on Fri, Nov 8. (Use the Earnings tab below to add this date to your calendar.)

RMTI Profile

Market Cap 200 Million
RMTI Description

Rockwell Medical Inc is a US-based fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease with its products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The company's drug products are Triferic and Calcitriol. Triferic is a therapy indicated to replace iron and maintain hemoglobin in adult hemodialysis patients with chronic kidney disease. It replaces the ongoing iron loss that occurs to patients during every hemodialysis treatment, via dialysate. Calcitriol is a generic drug for treating secondary hyperparathyroidism in dialysis patients. The company operates in one segment of hemodialysis market which involves the manufacture, sale, and distribution of hemodialysis products.


Visit Website

RMTI Earnings

EPS -0.18 P/E Ratio 0.00
Previous Thu, Aug 8, 2019
Latest Fri, Nov 8, 2019 (In 20 days)

RMTI Dividend

Yield --
Ex-Date --
Pay Date --
History --

RMTI Charts

$2.19
1 Year
$6.88
Dec 31, 2018
Mar 21, 2019



    TOP    
GALT $3.82 0.18 (4.50%)
Galectin Therapeutics Inc
NASDAQ: GALT $200 Million Small-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 25%. 1 Year Return 23%. 2019 YTD Return 1%. Negative 5 year, 1 year & YTD returns. You may want to avoid this one until things turn around. Check out some Uptrending symbols instead. Earnings in 24 days on Tue, Nov 12. (Use the Earnings tab below to add this date to your calendar.)

GALT Profile

Market Cap 200 Million
GALT Description

Galectin Therapeutics Inc is a biotechnology company. The company is focused on discovery and development. It is engaged in galectin science and drug development to create new therapies to improve the lives of patients with chronic liver and skin diseases and cancer. Drug candidates based on carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function. Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of directly involved in multiple inflammatory, fibrotic, and malignant diseases. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH-related fibrosis.


Visit Website

GALT Earnings

EPS -0.06 P/E Ratio 0.00
Previous Fri, Aug 9, 2019
Latest Tue, Nov 12, 2019 (In 24 days)

GALT Dividend

Yield --
Ex-Date --
Pay Date --
History --

GALT Charts

$2.94
1 Year
$6.16
Aug 23, 2019
Nov 5, 2018



    TOP    
ADMS $3.98 0.02 (0.50%)
Adamas Pharmaceuticals Inc
NASDAQ: ADMS $180 Million Small-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 72%. 1 Year Return 78%. 2019 YTD Return 56%. Negative 5 year, 1 year & YTD returns. You may want to avoid this one until things turn around. Check out some Uptrending symbols instead. This is clearly Downtrending. Avoid for now. Earnings in 19 days on Thu, Nov 7. (Use the Earnings tab below to add this date to your calendar.)

ADMS Profile

Market Cap 180 Million
ADMS Description

Adamas Pharmaceuticals Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. It operates in one reportable segment: the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. The company generates its revenues primarily from the United States.


Visit Website

ADMS Earnings

EPS -0.90 P/E Ratio 0.00
Previous Thu, Aug 8, 2019
Latest Thu, Nov 7, 2019 (In 19 days)

ADMS Dividend

Yield --
Ex-Date --
Pay Date --
History --

ADMS Charts

52 Week Low $3.35 set on Thu, Oct 10, 2019
$3.35
1 Year
$18.78
Oct 10, 2019
Oct 19, 2018



    TOP    
MEIP $1.78 0.01 (0.56%)
MEI Pharma Inc
NASDAQ: MEIP $150 Million Small-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 78%. 1 Year Return 53%. 2019 YTD Return 32%. Negative 5 year, 1 year & YTD returns. You may want to avoid this one until things turn around. Check out some Uptrending symbols instead. Earnings in 26 days on Thu, Nov 14. (Use the Earnings tab below to add this date to your calendar.)

MEIP Profile

Market Cap 150 Million
MEIP Description

MEI Pharma Inc is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes ME-401, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer. Geographically, all the business activities are functioned through the region of the United States.


Visit Website

MEIP Earnings

EPS 0.04 P/E Ratio 0.00
Previous Wed, Aug 28, 2019
Latest Thu, Nov 14, 2019 (In 26 days)

MEIP Dividend

Yield --
Ex-Date --
Pay Date --
History --

MEIP Charts

$1.44
1 Year
$4.05
Aug 15, 2019
Oct 19, 2018



    TOP    
CORV $2.00 0.00 (0.00%)
Correvio Pharma Corp. - Ordinary Shares (Canada)
NASDAQ: CORV $130 Million Small-Cap. Health Care Sector. Drug Manufacturers Industry. 5 Year Return 74%. 1 Year Return 39%. 2019 YTD Return 18%. Negative 5 year, 1 year & YTD returns. You may want to avoid this one until things turn around. Check out some Uptrending symbols instead. Earnings in 17 days on Tue, Nov 5. (Use the Earnings tab below to add this date to your calendar.)

CORV Profile

Market Cap 130 Million
CORV Description

Correvio Pharma Corp is specialty pharmaceutical company. It offers patients and healthcare providers therapeutic solutions for acute medical conditions to improve health and quality of life. Its products are Aggrastat, Esmocard, Brinavess, Xydalba, Zevtera/Mabelio, and others. It offers solutions on Acute Bacterial Skin and Skin Structure Infections, Acute Coronary Syndromes, Atrial Fibrillation, Hospital Acquired Pneumonia & Community Acquired Pneumonia, Pulmonary Arterial Hypertension, and Supraventricular Tachycardia. The firm earns revenue from the sale of company's commercialized products. It has Europe and Rest of the world geographic segments.


Visit Website

CORV Earnings

EPS -0.26 P/E Ratio 0.00
Previous Wed, Aug 14, 2019
Latest Tue, Nov 5, 2019 (In 17 days)

CORV Dividend

Yield --
Ex-Date --
Pay Date --
History --

CORV Charts

$1.43
1 Year
$4.44
Aug 7, 2019
Mar 13, 2019



    TOP    
Page 1 of 2


Symbol Price Day Δ YTD Δ
ACB $3.68 -5.40% -29.77%
ACET $0.13 -27.78% -85.23%
ADMP $0.54 -3.57% -77.41%
ADMS $3.98 -0.50% -56.12%
AERI $20.51 -3.48% -43.53%
AGRX $1.19 0.00% 65.28%
AKRX $4.61 -1.91% 32.47%
ALIM $0.34 -5.56% -60.00%
ALQA $0.00 0.00% -100.00%
AMPH $19.93 -2.88% 0.86%
AMRX $2.99 -0.66% -78.79%
APHA $4.75 -3.65% -20.97%
AQXP $0.00 0.00% -100.00%
ARDM $0.12 -73.91% -67.57%
ASRT $1.17 -6.40% -70.60%
ATXI $5.29 -2.58% -4.68%
AZN $43.87 -0.59% 16.06%
BHC $22.54 -1.14% 11.42%
BNTC $0.66 0.00% -56.00%
BPTH $10.99 3.19% 189.21%
CGC $20.21 -2.65% -30.12%
COLL $11.56 -4.30% -35.06%
CORV $2.00 0.00% -18.03%
CPIX $5.54 5.12% -13.98%
CPRX $5.25 -0.94% 148.82%
CRON $8.32 -6.09% -26.44%
CTLT $48.63 -2.21% 57.33%
DPLO $5.16 0.19% -62.55%